Postmenopausal metastatic breast cancer: A review of first-line treatment options

American Journal of Cancer

Volumn 2, Issue 2, 2003, Pages 95-109

  Assersohn, Laura ^a   Johnston, Stephen R D ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ARZOXIFENE; BENZOTHIOPHENE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FADROZOLE; FLUOROPYRIMIDINE CAPECITABINE; FULVESTRANT; GEFITINIB; GEMCITABINE; IDOXIFENE; LETROZOLE; NAVELBINE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; TAMOXIFEN; TAXANE DERIVATIVE; TIPIFARNIB; TOREMIFENE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CARCINOMA; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG RESEARCH; DRUG RESPONSE; HORMONAL THERAPY; HUMAN; MORBIDITY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PREDICTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKELETON; TOXICITY;

EID: 0037931457     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200302020-00003     Document Type: Review

References (101)

1. Office for National Statistics. Mortality statistics: review of the Register General on deaths by sex and age, England and Wales, 1999. London: The Stationery Office, 2000
2. Cancer Research Campaign, Cancer Research Campaign, CRC Cancer Stats; Mortality UK, London. Available from URL: http://www.crc.org.uk/cancer/pageimages/csmortality.pdf [Accessed 2002 Jul 19]
3. Greenberg P, Hortobagyi G, Smith T, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-205
4. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-42
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-67
6. Rubens R, Bajetta E, Bonneterre J, et al. Treatment of relapse of breast cancer after adjuvant systemic therapy. Eur J Cancer 1994; 30A: 106-11
7. Encarnacion C, Ciocca D, McGuire W, et al. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 1993; 26: 237-46
8. Johnston SR, Saccani Jotti G, Smith IE, et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995; 55 (15): 3331-8
9. Goldhirsch A. Breast cancer. In: Cavalli F, Hansen H, Kaye S, editors. Textbook of medical oncology. London: Martin Dunitz, 1997: 53-87
10. Johnston SRD. Acquired tamoxifen resistance in human breast cancer: potential mechanisms and clinical implications. Anticancer Drugs 1997; 8 (10): 911-30
11. Howell A, DeFriend D, Robertson J, et al. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995; 345: 29-30
12. Howell A, Robertson JRF, Albano J, et al. Fulvestrant is as effective as anastrozole in post-menopausal women with advanced breast cancerprogressing after prior treatment. J Clin Oncol 2002; 16: 3396-402
13. Osbourne CK, Pippen J, Jones SE, et al. Double-blind randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in post-menopausal women with advanced breast cancer progressing after prior endocrine therapy. J Clin Oncol 2002; 16: 3386-95
14. Johnston S. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res 2001; 7 Suppl. 1: 4376s-87s
15. Gradishar W, Glusman J, Vogel C, et al. Raloxifene HCL, a new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer. Breast Cancer Res Treat 1997; 46: 53
16. Cummings S, Eckert S, Krueger K, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the multiple outcomes of raloxifene evaluation (MORE) randomized trial. JAMA 1999; 281: 2189-97
17. Fisher B, Costantino J, Wickerham D, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90 (18): 1371-88
18. Brodie A, Njar V. Aromatase inhibitors and breast cancer. Semin Oncol 1996; 23 (4 Suppl. 9): 10-20
19. Miller WR. Aromatase inhibitors. Endocr Relat Cancer 1996; 3 (1): 65-79
20. Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002; 20: 751-57
21. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in post-menopausal women with advanced breast cancer: results of overview analysis of 2 phase III trials. J Clin Oncol 1996; 14: 2000-11
22. Buzdar A, Jonat W, Howell A, et al. Anastrozole vs megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998; 83: 1142-52
23. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16 (2): 453-61
24. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 19 (14): 3357-66
25. Kvinnsland S, Anker G, Dirix L, et al. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 2000; 36: 976-82
26. Lonning P, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000; 18 (11): 2234-44
27. Thurlimann B, Paridaens R, Serin D, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study: Exemestane Study Group. Eur J Cancer 1997; 33 (11): 1767-73
28. Kaufmann M, Bajetta E, Dirix L, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000; 18 (7): 1399-411
29. Nabholtz J, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000; 18 (22): 3758-67
30. Bonneterre J, Thurlimann B, Robertson J, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000; 18 (22): 3748-57
31. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19 (10): 2596-606
32. Dirix L, Piccart M, Lohrisch C, et al. Efficacy of and tolerance to exemestane versus tamoxifen in first line hormone therapy of postmenopausal metastatic breast cancer patients: a European Organisation for the Research and Treatment of cancer (EORTC Breast Group) Phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 2001; 20: 114a
33. Buzdar A, Nabholtz J, Robertson J, et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal (PM) women - combined analysis from two identically designed multicenter trials [abstract 609D]. Proc Am Soc Clin Oncol 2000; 19: 154A
34. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC Randomised Trial. Lancet 2002; 359: 2131-9
35. Cold S, Jensen N, Brincker H. The influence of chemotherapy on survival after recurrence in breast cancer: a population based study of patients treated in the 1950s, 1960s, and 1970s. Eur J Cancer 1993; 29: 1146-52
36. Geels P, Eisenhauer E, Bezjak A, et al. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 2000; 18 (12): 2395-405
37. Falkson G, Gelman R, Glick J, et al. Metastatic breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obtained following doxorubicin induction treatment: an Eastern Cooperative Oncology Group study. Ann Oncol 1992; 3 (9): 768-70
38. Falkson G, Gelman R, Pandya K, et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998; 16 (5): 1669-76
39. Muss H, Case L, Richards II F, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 1991; 325 (19): 1342-8
40. Perez E. Current management of metastatic breast cancer. Semin Oncol 1999; 26 (4 Suppl. 12): 1-10
41. Camaggi C, Strocchi E, Carisi P. Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. Cancer Chemother Pharmacol 1993; 32: 301-9
42. French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and with either doxorubicin or epirubicin. J Clin Oncol 1988; 6: 679-88
43. French Epirubicin Study Group. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cylophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 1991; 9: 305-12
44. Biganzoli L, Piccart M. The bigger the better? Or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer. Ann Oncol 1997; 8: 1177-82
45. Buzdar A, Hortobagyi G, Prye D, et al. Second-line chemotherapy for metastatic breast cancer including quality of life issues. Breast 1996; 5: 312-7
46. Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure: a randomised phase III study with cross-over on progression by the Scandinavian Breast Cancer Group. Eur J Cancer 1999; 35: 1194-201
47. Nabholtz J, Senn J, Beswoda W, et al. Prospective randomised trial of docetaxel vs mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999; 17: 1413-24
48. Bonneterre J, Roche H, Monnier A, et al. Taxotere vs 5-FU and Navelbine as second-line chemotherapy in patients wiith metastatic breast cancer. Proc Am Soc Clin Oncol 1997; 16: A564
49. Chan S, Friedrichs K, Noel D, et al. Prospective randomised phase III trial of docetaxel vs doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-54
50. Sledge GW, Neuberg D, Bernando P, et al. Phase III trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as front-line chemotherapy for metastatic breast cancer; an intergroup trial [abstract]. J Clin Oncol 2003; 21: 588-92
51. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel vs doxorubicin as first-line single agent chemotherapy for metastatic breast caner: a European Organisation for Research and Treatment of Cancer randomised study with cross-over. J Clin Oncol 2000; 18: 724-33
52. Bishop J, Dewar J, Toner G, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999; 17: 2355-64
53. Perez EA, Vogel CL, Irwin DH, Krishner JJ, Patel R. Multicenter Phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001: 18: 4216-33
54. Burstein H, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 19: 1212-9
55. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophopshamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19 (6): 1707-15
56. Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first line chemtoherapy in metastatic breast cancer: the European Organisation for Research and Treatment of cancer 10961 multicenter phase III trial. J Clin Oncol 2002; 20: 3114-21
57. Luck H, Thomssen C, Untch M, et al. Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC): epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC) - a study of the AGO Breast Cancer Group. Proc Am Soc Clin Oncol 2000; 19: 73A
58. Carmichael J. UKCCR trial of epirubicin and cyclophosphamide vs epirubicin and taxolin the first line treamtnet of women with metastatic breast cancer [abstract 84a]. Proc Am Soc Clin Oncol 2001; 20: 22
59. Nabholtz J-M, Falkson G, Campos D, et al. Doccetexal and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast caner; results of a randomised, multicenter phase III trial. J Clin Oncol 2003; 21: 968-75
60. Mackey J, Paterson A, Dirix L, et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy for patients with metastatic breast cancer [abstract 137]. Proc Am Soc Clin Oncol 2002; 21: 35a
61. Sparano J, O'Neill A, Schaefer P, et al. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimultating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol 2000; 18: 2369-77
62. Sparano J, Hu P, Rao R, et al. Phase II trial of doxorubicn and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1999; 17: 3828-34
63. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13 (11): 2688-99
64. Nabholtz J, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer aptients: interim analysis of the BCIRG 001 study [abstract 141]. Proc Am Soc Clin Oncol 2002; 21: 36a
65. Buzdar AU, Singletary SE, Valero V, et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer; preliminary results of a prospective randomised trial. Clin Cancer Res 2002; 8: 1073-9
66. Blum J, Jones S, Buzdar A, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-93
67. O'Shaughnessy J, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12 (9): 1247-54
68. Engelsman E, Klijn J, Rubens R, et al. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: an EORTC Breast Cancer Co-Operative Group Phase III Trial (10808). Eur J Cancer 1991; 27 (8): 966-70
69. Fumoleau P, Largillier R, Trillet-Lenoir V, et al. Capecitabine (Xeloda) in patients with advanced breast cancer, previously treated with anthracyclines and taxanes: results of a large phase II study [abstract 247]. Proc Am Soc Clin Oncol 2002; 21: 62a
70. Degardin M, Bonneterre J, Hecquet B, et al. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994; 5: 423-6
71. Marty M, Extra J, Dieras V, et al. A review of the antitumour activity of vinorelbine in breast cancer. Drugs 1992; 44 Suppl. 4: 29-35
72. Jones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995; 13 (10): 2567-74
73. Spielmann M, Kalla S, Llombart-Cussac A, et al. Activity of gemcitabine in metastatic breast cancer patients previously treated with anthracycline-containing regimens. Eur J Cancer 1997; 33 Suppl. 8: A663
74. Brodowicz T, Moslinger R, Herscovici V, et al. Second- and third-line treatent of metastatic breast cancer with gemcitabine. Eur J Cancer 1998; 34 Suppl. 5: A180
75. Rahman Z, Frye D, Buzdar A, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997; 15: 3171-7
76. Lotz J, Cure H, Janvier M, et al. High-dose chemotherapy with haemopoietic transplantation for metastatic breast cancer: results of the French protocol PEGASE 04 [abstract 161]. Proc Am Soc Clin Oncol 1999; 18: 43a
77. Stadtmauer E, O'Neill A, Goldstein L, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous haematopoetic stem cell transplant group. N Engl J Med 2000; 342: 1069-76
78. Stadtmauer E, O'Neill A, Goldstein L, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous stem-cell transplantation for metastatic breast cancer: 5-year update of the "Philadelphia Trial" [abstract 169]. Proc Am Soc Clin Oncol 2002; 21: 43a
79. Paterson A, Powles T, Kanis J, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65
80. Conte P, Latrielle J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. J Clin Oncol 1996; 14: 2552-9
81. Hortobagyi G, Theriault R, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785-91
82. Lipton A, Theriault R, Hortobagyi G, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 2000; 88: 1082-90
83. Theriault R, Lipton A, Hortobagyi G, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial-protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846-54
84. Breast Specialty Group of the British Association of Surgical Oncology. The management of metastatic bone disease in the United Kingdom. Eur J Surg Oncol 1999; 25: 3-23
85. Hillner B, Ingle J, Berenson J, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer: American Society of Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000; 18: 1378-91
86. Diel I, Marschner N, Kindler M, et al. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases [abstract 488A]. Proc Am Soc Clin Oncol 1999; 18: 128
87. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235 (4785): 177-82
88. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized Anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14 (3): 737-44
89. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16 (8): 2659-71
90. Cobleigh M, Vogel C, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressiing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17 (9): 2639-48
91. Vogel C, Cobleigh M, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20 (3): 719-26
92. Slamon J, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpreses HER2. N Engl J Med 2001; 344: 783-92
93. Seidman A, Hudis C, Pierri M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20 (5): 1215-21
94. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-63
95. Sirotnak F, Zakowski M, Miller V, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibtor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885-92
96. Jeng M, Yue W, Eischied A, et al. Role of MAP kinase in the enhanced cell proliferation of long-term estrogen deprived human breast cancer cells. Breast Cancer Res Treat 2000; 62: 167-75
97. McClelland R, Barrow D, Madden T, et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001; 142 (7): 2776-88
98. Nicholson R, Hutcheson I, Harper M, et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 2001; 8: 175-82
99. Gee J, Hutcheson I, Knowlden J, et al. The EGFR-selective tyrosine kinase inhibitor ZD1839 (Iressa) is an effective inhibitor of tamoxifen-resistant breast cancer growth. Proc Am Soc Clin Oncol 2001; 20: A282
100. Clark G, Der CJ. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 1995; 35: 133-44
101. Johnston S, Hickish T, Ellis P, et al. Clinical activity with the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer: relationship with tumour phenotype. Breast Cancer Res Treat 2000; 32: A28